CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to enhance cancer therapy by identifying proteins that influence the activity of PARP1, a target in treating breast and ovarian cancers. It focuses on understanding resistance to PARP1 inhibitors through a systems biology approach, combining computational and experimental methods to uncover potential…
Inhibition of PARP1 in cancer therapy is a recently adopted strategy to treat cancers where DNA repair is defective, such as breast and ovarian cancer caused by mutations in BRCA1 or BRCA2.
In addition, PARP1 inhibitors (PARPi) can be useful even in the absence of BRCA mutations, likely due to pathogenic variants or epigenetic inactivation of other DNA repair related genes.
However, development of resistance to PARPi is a significant challenge.To address this challenge, I propose to identify pro…
CONSIGLIO NAZIONALE DELLE RICERCHE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC
United States, Tampa Fl
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
